Journal of B.U.ON. : official journal of the Balkan Union of Oncology · 2020
The expression pattern of ACTBL2 in thymoma reveals its potential therapeutic target efficacy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Ming, Meng Qingxin
Аннотация
PURPOSE: Thymoma is a thymic epithelial tumor characterized by the presence of epithelial cells and lymphocytes in the thymus. Although the incidence of thymoma is not high, we know very little about its treatment mechanism. Therefore, this study was intended to explore its potential targets and provide a new approach for perfect targeted therapy.
METHODS: We identified a series of non-coding (nc) RNAs (including BCL11A, miR-3977, miR-4460 and miR-542-3p) and TF (FAM185A, MGAM2, SEC14L4, ACTBL2), and predicted transcription factors (including AHR, ATF4, CEBPA and DDIT3) that have significant regulatory effects on the module by difference analysis, co-expression analysis, enrichment analysis of thymoma gene expression profiling and using hypergeometric test to calculate the potential regulatory effects of multiple factors on the module.
RESULTS: We obtained 15 modules from the thymoma dysfunction modules and found that the module genes are involved in a variety of immune-related biological functions. For example, neutrophil activation involved in immune response, neutrophil mediated immunity and response to extracellular stimulus indicate that neutrophil-mediated regulation plays an important regulatory role in the thymoma disorder module.
CONCLUSION: Overall, a dysfunction module for thymoma was identified, and significant pivotal regulators in the module were used as important components of thymoma molecular dysregulation, of which ACTBL2 could serve as a potential therapeutic target in thymoma, which provides an effective theoretical reference for subsequent researchers.
METHODS: We identified a series of non-coding (nc) RNAs (including BCL11A, miR-3977, miR-4460 and miR-542-3p) and TF (FAM185A, MGAM2, SEC14L4, ACTBL2), and predicted transcription factors (including AHR, ATF4, CEBPA and DDIT3) that have significant regulatory effects on the module by difference analysis, co-expression analysis, enrichment analysis of thymoma gene expression profiling and using hypergeometric test to calculate the potential regulatory effects of multiple factors on the module.
RESULTS: We obtained 15 modules from the thymoma dysfunction modules and found that the module genes are involved in a variety of immune-related biological functions. For example, neutrophil activation involved in immune response, neutrophil mediated immunity and response to extracellular stimulus indicate that neutrophil-mediated regulation plays an important regulatory role in the thymoma disorder module.
CONCLUSION: Overall, a dysfunction module for thymoma was identified, and significant pivotal regulators in the module were used as important components of thymoma molecular dysregulation, of which ACTBL2 could serve as a potential therapeutic target in thymoma, which provides an effective theoretical reference for subsequent researchers.